EHR Specification Developments Now Underway for A/I Specialty Measures

The AAAAI Board of Directors has committed to investing in the further development of quality measures to better facilitate Electronic Health Records (EHR) connectivity to the AAAAI Allergy, Asthma and Immunology Quality Clinical Data Registry in Collaboration with CECity (AAAAI QCDR). These electronic specifications will also assist providers, including those not using the registry, in collecting data on specialty-specific measures for reporting to payers, systems or academic institutions. This development also enables use of specialty-specific measures for Meaningful Use reporting as well as for the Physician Quality Reporting System (PQRS) program in the QCDR.

The following measures will have electronic specifications developed:

1. Penicillin Allergy: Appropriate Removal or Confirmation
2. Asthma Control: Minimal Important Difference Improvement Measure
3. Allergen Immunotherapy Treatment: Allergen Specific Immunoglobulin E (IgE) Sensitivity Assessed and Documented Prior to Treatment
4. Documented Rationale to Support Long-Term Aeroallergen Immunotherapy Beyond Five years, as Indicated
5. Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year
6. Documentation of Clinical Response to Allergen Immunotherapy within One Year

These measures are a result of AAAAI development activities for the QCDR and also the work of the Joint AAAAI and ACAAI Task Force on Quality Performance Measures. For more information on quality measures in allergy/immunology, visit the AAAAI website.

For more information on the AAAAI QCDR, click here and be sure to bookmark the Quality Corner within the AAAAI Continuing Education Center.